Improving Adherence to Treatment and Reducing Economic Costs of Hypertension: The Role of Olmesartan-Based Treatment

High Blood Pressure and Cardiovascular Prevention

Volumn 24, Issue 3, 2017, Pages 265-274

  Costa, Francesco Vittorio ^a  

^a Madre Fortunata Toniolo Hospital   (Italy)

Author keywords

Adherence to treatment; Antihypertensive treatment; Fixed dose combinations; Generic drugs; Healthcare costs; Olmesartan

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GENERIC DRUG; OLMESARTAN; IMIDAZOLE DERIVATIVE; TETRAZOLE DERIVATIVE;

ARTICLE; BLOOD PRESSURE REGULATION; DRUG CHOICE; DRUG COST; DRUG SUBSTITUTION; HEALTH ECONOMICS; HUMAN; HYPERTENSION; MEDICATION COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL; BLOOD PRESSURE; COMBINATION DRUG THERAPY; COST BENEFIT ANALYSIS; COST CONTROL; DRUG EFFECTS; ECONOMICS; PATHOPHYSIOLOGY; TIME FACTOR; TREATMENT OUTCOME;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; COST SAVINGS; COST-BENEFIT ANALYSIS; DRUG COSTS; DRUG SUBSTITUTION; DRUG THERAPY, COMBINATION; DRUGS, GENERIC; HUMANS; HYPERTENSION; IMIDAZOLES; MEDICATION ADHERENCE; OLMESARTAN MEDOXOMIL; TETRAZOLES; TIME FACTORS; TREATMENT OUTCOME;

EID: 85028544713     PISSN: 11209879     EISSN: 11791985     Source Type: Journal    
DOI: 10.1007/s40292-017-0221-4     Document Type: Article

References (82)

1. Yiannakopoulou EC, Papadopulos JS, Cokkinos DV, Mountokalakis TD. Adherence to antihypertensive treatment: a critical factor for blood pressure control. Eur J Cardiovasc Prev Rehabil. 2005;12:243–9.
2. Sabatè E. Adherence to long-term therapies: evidence for action. Geneva: World Health Organization; 2003.
3. Brown MT, Bussell JK. Medication adherence: WHO cares? Mayo Clin Proc. 2011;86(4):304–14.
4. Shaw E, Anderson J, Maloney M, Jay S, Fagan D. Factors associated with noncompliance of patients taking antihypertensive medications. Hosp Pharm. 1995;30:201–7.
5. Costa FV. Compliance with antihypertensive treatment. Clin Exp Hypertens. 1996;18(3–4):463–72.
6. Berg JS, Dischler J, Wagner DJ, Raia JJ, Palmer-Shevlin N. Medication compliance: a healthcare problem. Ann Pharmacother. 1993;27(9 Suppl):S1–24.
7. DiMatteo MR, Giordani PJ, Lepper HS, Croghan TW. Patient adherence and medical treatment outcomes: a meta-analysis. Med Care. 2002;40:794–811.
8. Bloom BS. Continuation of initial antihypertensive medication after 1 year of therapy. Clin Ther. 1998;20:1–11.
9. Corrao G, Zambon A, Parodi A, Poluzzi E, Baldi I, Merlino L, Cesana G, Mancia G. Discontinuation of and changes in drug therapy for hypertension among newly-treated patients: a population-based study in Italy. J Hypertens. 2008;26:819–24.
10. Mazzaglia G, Mantovani LG, Sturkenboom MC, Filippi A, Trifirò G, Cricelli C, Brignoli O, Caputi AP. Patterns of persistence with antihypertensive medications in newly diagnosed hypertensive patients in Italy: a retrospective cohort study in primary care. J Hypertens. 2005;23(11):2093–100.
11. Costa FV, Degli Esposti L, Cerra C, Veronesi C, Buda S. Trends in prescription and determinants of persistence to antihypertensive therapy: The PAPEETE study. High Blood Press Cardiovasc Prev. 2009;16(4):167–76.
12. Cherry SB, Benner JS, Hussein MA, Tang SSK, Nichol MB. The clinical and economic burden of non adherence with antihypertensive and lipid-lowering therapy in hypertensive patients. Value Health. 2009;12(4):489–97.
13. Degli Esposti L, Valpiani G. Pharmacoeconomic burden of undertreating hypertension. Pharmacoeconomics. 2004;22(14):907–28.
14. Degli Esposti L, Saragoni S, Benemei S, Batacchi P, Geppetti P, Di Bari M. Adherence to antihypertensive medications and health outcomes among newly treated hypertensive patients. Clinicoecon Outcomes Res. 2011;3:47–54.
15. Rasmussen JN, Chong A, Alter DA. Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA. 2007;297:177–86.
16. Breekveldt-Postma NS, Penning-van Beest FJ, Siiskonen SJ, Koerselman J, Klungel OH, Falvey H, Vincze G, Herings RM. The effect of discontinuation of antihypertensives on the risk of acute myocardial infarction and stroke. Curr Med Res Opin. 2008;24:121–7.
17. Mazzaglia G, Ambrosioni E, Alacqua M, Filippi A, Sessa E, Immordino V, Borghi C, Brignoli O, Caputi AP, Cricelli C, Mantovani LG. Adherence to antihypertensive medications and cardiovascular morbidity among newly diagnosed hypertensive patients. Circulation. 2009;120:1598–605.
18. Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care. 2005;43:521–30.
19. Muszbek N, Brixner D, Benedict A, Keskinaslan A, Khan ZM. The economic consequences of noncompliance in cardiovascular disease and related conditions: a literature review. Int J Clin Pract. 2008;62(2):338–51.
20. Dragomir A, Côté R, Roy L, Blais L, Lalonde L, Bérard A, Perreault S. Impact of adherence to antihypertensive agents on clinical outcomes and hospitalization costs. Med Care. 2010;48(5):418–25.
21. Mennini FS, Marcellusi A, von der Schulenburg JM, Gray A, Levy P, Sciattella P, Soro M, Staffiero G, Zeidler J, Maggioni A, Schmieder RE. Cost of poor adherence to anti-hypertensive therapy in five European countries. Eur J Health Econ. 2015;16(1):65–72.
22. Allender S, Scarborough P, Peto V, Rayner M, Leal J, Luengo-Fernandez R, Gray A. European cardiovascular disease statistics. Brussels: European Heart Network; 2008.
23. Hansson L, Lloyd A, Anderson P, Kopp A. Excess morbidity and cost of failure to achieve targets for blood pressure control in Europe. Blood Press. 2002;11(1):35–45.
24. Roebuck MC, Liberman JN, Gemmill-Toyama MA, Brennan TA. Medication adherence leads to lower health care use and costs despite increased drug spending. Health Aff. 2011;30(1):91–9.
25. Pittman DG, Tao Z, Chen W, Stettin GD. Antihypertensive medication adherence and subsequent healthcare utilization and costs. Am J Manag Care. 2010;16(8):568–76.
26. Andersen ML, Laursen K, Schaumann M, Rubak SL, Olesgaard P, Mainz J, Lauritzen T. How do patients evaluate the newly introduced system of substituting prescriptions? Ugeskr Læger. 2000;162(45):6066–9.
27. Hakonsen H, Eilertsen M, Borge H, Toverud EL. Generic substitution: additional challenge for adherence in hypertensive patients? Curr Med Res Opin. 2009;25(10):2515–21.
28. Van Wijk BL, Klungel OH, Heerdink ER, de BA. Generic substitution of antihypertensive drugs: does it affect adherence? Ann Pharmacother. 2006;40(1):15–20.
29. Eaddy MT, Cook CL, O’Day K, Burch SP, Cantrell CR. How patient cost-sharing trends affect adherence and outcomes a literature review. P&T®. 2012;37(1):45–55.
30. Briesacher BA, Andrade SE, Fouayzi H, Chan KA. Medication adherence and use of generic drug therapies. Am J Manag Care. 2009;15:450–6.
31. Shrank WH, Hoang T, Ettner SL, Glassman PA, Nair K, DeLapp D, Dirstine J, Avorn J, Asch SM. The implications of choice: prescribing generic or preferred pharmaceuticals improves medication adherence for chronic conditions. Arch Intern Med. 2006;166:332–7.
32. Taira DA, Wong KS, Frech-Tamas F, Chung RS. Copayment level and compliance with antihypertensive medication: analysis and policy implications for managed care. Am J Manag Care. 2006;12:678–83.
33. Sedjo RL, Cox ER. Lowering copayments: impact of simvastatin patent expiration on patient adherence. Am J Manag Care. 2008;14:813–8.
34. Després F, Forget A, Kettani FZ, Blais L. Impact of patient reimbursement timing and patient out-of-pocket expenses on medication adherence in patients covered by private drug insurance plans. J Manag Care Spec Pharm. 2016;22(5):539–47.
35. Briesacher BA, Andrade SE, Fouayzi H, Chan KA. Medication adherence and the use of generic drug therapies. Am J Manag Care. 2009;15(7):450–6.
36. Corrao G, Soranna D, La Vecchia C, Catapano A, Agabiti-Rosei E, Gensini G, Merlino L, Mancia G. Medication persistence and the use of generic and brand-name blood pressure-lowering agents. J Hypertens. 2014;32(5):1146–53. doi:10.1097/HJH.0000000000000130.
37. Colombo GL, Agabiti-Rosei E, Margonato A, Mencacci C, Montecucco CM, Trevisan R. Off-patent generic medicines vs. off-patent brand medicines for six reference drugs: a retrospective claims data study from five local healthcare units in the lombardy region of Italy. PLoS One. 2013;8(12):e82990. doi:10.1371/journal.pone.0082990.
38. Weissenfeld J, Stock S, Lüngen M, Gerber A. The nocebo effect: a reason for patients’ non-adherence to generic substitution? Pharmazie. 2010;65:451–6.
39. Faasse K, Petrie KJ. The nocebo effect: patient expectations and medication side effects. Postgrad Med J. 2013;89(1055):540–6.
40. Kesselheim AS, Bykov K, Avorn J, Tong A, Doherty M, Choudhry NK. Burden of changes in pill appearance for patients receiving generic cardiovascular medications after myocardial infarction: cohort and nested case-control studies. Ann Intern Med. 2014;161(2):96–103.
41. Golightly LK, Smolinske SS, Bennett ML, Sutherland EW, Rumack BH. Pharmaceutical excipients. Adverse effects associated with inactive ingredients in drug products (part I). Med Toxicol Adverse Drug Exp. 1988;3(2):128–65.
42. Strauss J. Excipient-related adverse drug reactions a clinical approach. Curr Allergy Clin Immunol. 2015;28(1):24–7.
43. Stafylas AJP, Stergiou GS. Effectiveness, safety and cost of drug substitution in hypertension. Br J Clin Pharmacol. 2010;70(3):320–34.
44. Harris Interactive. Consumers’ views on therapeutic substitution. http://www.nclnet.org/health/therapeutic_substitution.pdf (2008). Accessed 15 June 2009.
45. Yim DS. Simulation of the AUC changes after generic substitution in patients. J Korean Med Sci. 2009;24(1):7–12.
46. Colombo GL, Agabiti-Rosei E, Margonato A, Mencacci C, Montecucco CM, Trevisan R, Catapano AL. Impact of substitution among generic drugs on persistence and adherence: a retrospective claims data study from 2 Local Healthcare Units in the Lombardy Region of Italy. Atheroscler Suppl. 2016;21:1–8. doi:10.1016/j.atherosclerosissup.2016.02.001.
47. Thayer S, Dastani H. Can switching among the ARB class impact medical costs and medication adherence? J Manag Care Pharm. 2009;15:179.
48. Wilson J, Axelsen K, Tang S. Medicaid prescription drug access restrictions: exploring the effect on patient persistence with hypertension medications. Am J Manag Care. 2005;11:SP27–34.
49. Degli Esposti L, Sangiorgi D, Buda S, Degli Esposti E, Scaglione F. Therapy discontinuation or substitution in patients with cardiovascular disease, switching among different products of the same off-patent active substance: a ‘real-world’ retrospective cohort study. BMJ Open. 2016;6:e012003.
50. Paveliu MS, Bengea S, Paveliu FS. Generic substitution issues: brand-generic substitution, generic-generic substitution, and generic Substitution of Narrow Therapeutic Index (NTI)/critical dose drugs. J Clin Med. 2011;6(1):52–8.
51. Bloom BS. Daily regimen and compliance with treatment. BMJ. 2001;323:647.
52. Eisen SA, Miller DK, Woodward RS, Spitznagel E, Przybeck TR. The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med. 1990;150(9):1881–4.
53. Xie L, Frech-Tamas F, Marrett E, Baser O. A medication adherence and persistence comparison of hypertensive patients treated with single-, double- and triple-pill combination therapy. Curr Med Res Opin. 2014;30(12):2415–22.
54. Khan MU, Shah S, Hameed T. Barriers to and determinants of medication adherence among hypertensive patients attended National Health Service Hospital, Sunderland. J Pharm Bioallied Sci. 2014;6(2):104–8.
55. Svensson S. Medication adherence, side effects and patient-physician interaction in hypertension. Thèse de Doctorat en Médecine. Suède: Université de Goteborg. 2006, 65f.
56. Vrijens B, Vincze G, Kristanto P, Urquhart J, Burnier M. Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. BMJ. 2008;336(7653):1114–7.
57. Kario K. Morning surge in blood pressure and cardiovascular risk. Evidence and perspectives. Hypertension. 2010;56:765–73.
58. Costa FV, D’Ausilio A, Bianchi C, Negrini C, Lopatriello S. Adherence to antihypertensive medications a review and update. High Blood Press Cardiovasc Prev. 2009;16:101.
59. Conlin PR, Gerth WC, Fox J, Roehm JB, Boccuzzi SJ. Four-year persistence patterns among patients initiating therapy with the angiotensin II receptor antagonist losartan versus other artihypertensive drug classes. Clin Ther. 2001;23(12):1999–2010.
60. Kronish IM, Woodward M, Sergie Z, Ogedegbe G, Falzon L, Mann DM. Meta-analysis: impact of drug class on adherence to antihypertensives. Circulation. 2011;123(15):1611–21.
61. Mazzaglia G, Mantovani LG, Sturkenboom MC, Filippi A, Trifirò G, Cricelli C, Brignoli O, Caputi AP. Patterns of persistence with antihypertensive medications in newly diagnosed hypertensive patients in Italy: a retrospective cohort study in primary care. J Hypertens. 2005;23(11):2093–100.
62. Redon J, Fabia MJ. Efficacy in angiotensin receptor blockade: a comparative review of data with olmesartan. J Renin Angiotensin Aldosterone Syst. 2009;10(3):147–56.
63. Saseen JJ. Review of olmesartan medoxomil in achieving guideline-recommended target BP goals and implications for managed care. Curr Hypertens Rev. 2012;8:190–5.
64. Kourlaba G, Gialama F, Tsioufis K, Maniadakis N. A literature review to evaluate the clinical and economic value of olmesartan for the treatment of hypertensive patients. Int J Cardiol. 2016;221:60–7.
65. Brunner HR. Clinical efficacy and tolerability of olmesartan. Clin Ther. 2004;26(Supplement A):A28–32.
66. Sherrill B, Halpern M, Khan S, Zhang J, Panjabi S. Single-pill vs free-equivalent combination therapies for hypertension: a meta-analysis of health care costs and adherence. J Clin Hypertens (Greenwich). 2011;13(12):898–909.
67. Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension. 2010;55(2):399–407.
68. Gradman AH, Parisé H, Lefebvre P, Falvey H, Lafeuille MH, Duh MS. Initial combination therapy reduces the risk of cardiovascular events in hypertensive patients: a matched cohort study. Hypertension. 2013;61(2):309–18.
69. Dickson M, Plauschinat CA. Compliance with antihypertensive therapy in the elderly: a comparison of fixed-dose combination amlodipine/benazepril versus component-based free-combination therapy. Am J Cardiovasc Drugs. 2008;8(1):45–50.
70. Tung YC, Lin YS, Wu LS, Chang CJ, Chu PH. Clinical outcomes and healthcare costs in hypertensive patients treated with a fixed-dose combination of amlodipine/valsartan. J Clin Hypertens (Greenwich). 2015;17(1):51–8.
71. Yang W, Chang J, Kahler KH, Fellers T, Orloff J, Wu EQ, Bensimon AG. Evaluation of compliance and health care utilization in patients treated with single pill vs. free combination antihypertensives. Curr Med Res Opin. 2010;26(9):2065–76.
72. Baser O, Andrews LM, Wang L, Xie L. Comparison of real-world adherence, healthcare resource utilization and costs for newly initiated valsartan/amlodipine single-pill combination versus angiotensin receptor blocker/calcium channel blocker free-combination therapy. J Med Econ. 2011;14(5):576–83.
73. Kumagai N, Onishi K, Hoshino K, Nakamori S, Kitai T, Yazu T, Oota M, Ueda Y, Hiraoka N, Okamoto S, Yamada T, Dohi K, Nakamura M, Ito M. Improving drug adherence using fixed combinations caused beneficial treatment outcomes and decreased health-care costs in patients with hypertension. Clin Exp Hypertens. 2013;35(5):55–60.
74. Volpe M, de la Sierra A, Kreutz R, Laurent S, Manolis AJ. ARB-based single-pill platform to guide a practical therapeutic approach to hypertensive patients. High Blood Press Cardiovasc Prev. 2014;21:137.
75. McIntyre H, Costa FV, Düsing R, Ambrosioni E, Gerth W. The role of losartan in cost-effective hypertension control. Curr Med Res Opin. 2002;18(3):139–45.
76. Theodoratou D, Maniadakis N, Fragoulakis V, Stamouli E. Analysis of published economic evaluations of angiotensin receptor blockers. Hell J Cardiol. 2009;50:105–18.
77. Boersma C, Voors AA, Visser ST, de Jong-van den Berg LT, Postma MJ. Cost effectiveness of angiotensin receptor blocker monotherapy in patients with hypertension in the Netherlands: a comparative analysis using clinical trial and drug utilization data. Am J Cardiovasc Drugs. 2010;10(1):49–54.
78. Miller LA, Wade R, Dai D, Cziraky MJ, Ramaswamy K, Panjabi S. Economic evaluation of four angiotensin II receptor blockers in the treatment of hypertension. Curr Med Res Opin. 2010;26(6):1307–20.
79. Oparil S, Williams D, Chrysant SG, Marbury TC, Neutel J. Comparative efficacy of olmesartan, losartan, valsartan and irbesartan in the control of essential hypertension. J Clin Hypertens (Greenwich). 2001;3(283–91):318.
80. Simons WR. Comparative cost effectiveness of angiotensin II receptor blockers in a US managed care setting: olmesartan medoxomil compared with losartan, valsartan and irbesartan. Pharmacoeconomics. 2003;21:61–74.
81. Belsey JD. Choice of angiotensin receptor blocker in moderate hypertension A UK-based cost–benefit comparison of olmesartan- and candesartan-based regimens. J Med Econ. 2011;14:5.
82. Kobayashi SM, Matsushita Y, Mori A, Kawasugi K, Saruta T. Cost-utility analysis of antihypertensive combination therapy in Japan by a Monte Carlo simulation model. Hypertens. Res. 2008;31:1373–83.